Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein.

C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc Natl Acad Sci U S A (2008) 1.32

The structure of Abeta42 C-terminal fragments probed by a combined experimental and theoretical study. J Mol Biol (2009) 1.19

Biophysical characterization of Abeta42 C-terminal fragments: inhibitors of Abeta42 neurotoxicity. Biochemistry (2010) 0.97

Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments. Biochemistry (2010) 0.96

C-terminal tetrapeptides inhibit Aβ42-induced neurotoxicity primarily through specific interaction at the N-terminus of Aβ42. J Med Chem (2011) 0.84

A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors. ChemMedChem (2012) 0.76

Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus. PLoS One (2016) 0.75

Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity. ACS Chem Neurosci (2016) 0.75

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04

Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med (1996) 10.44

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63

Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14

An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10

Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci (2003) 4.75

Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res (2002) 3.79

Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol (1995) 3.44

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42

Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging (2004) 3.13

Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06

Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci (2005) 2.57

On the nucleation of amyloid beta-protein monomer folding. Protein Sci (2005) 2.47

Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A (2003) 2.33

In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A (2004) 2.13

NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox). Eur J Biochem (2001) 2.02

Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol (1992) 1.90

Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol (1995) 1.75

Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J Am Chem Soc (2005) 1.23

Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study. Biophys J (2007) 1.22

Beta-sheet breakers for Alzheimer's disease therapy. Curr Drug Targets (2004) 1.07

Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett (1998) 1.01

Deaths attributable to Alzheimer's disease in the United States. Am J Public Health (1999) 1.00

Methyl dynamics of the amyloid-beta peptides Abeta40 and Abeta42. Biochem Biophys Res Commun (2007) 0.93

Amyloid-beta as a "difficult sequence" in solid phase peptide synthesis. Protein Pept Lett (2004) 0.91

The synthesis of 'difficult' peptides using 2-hydroxy-4-methoxybenzyl or pseudoproline amino acid building blocks: a comparative study. J Pept Sci (1999) 0.90

Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med Chem (2004) 0.90

Cost of Alzheimer's disease in a developing country setting. Int J Geriatr Psychiatry (2005) 0.88

Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord (2002) 0.86

Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? Expert Rev Neurother (2006) 0.84

The economics of Alzheimer disease. Dement Geriatr Cogn Disord (2003) 0.83

Synthesis and purification of amyloidogenic peptides. Anal Biochem (2001) 0.79

Inhibitors of amyloid aggregation: technologies for the discovery of novel lead compounds. Biotechnol Genet Eng Rev (2004) 0.78

Solid phase synthesis of hydrophobic difficult sequence peptides on BDDMA-PS support. J Pept Sci (2001) 0.77

'O-Acyl isopeptide method' for the efficient preparation of amyloid beta peptide 1-42 mutants. Bioorg Med Chem (2005) 0.77

In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A (2004) 2.13

Elucidation of amyloid beta-protein oligomerization mechanisms: discrete molecular dynamics study. J Am Chem Soc (2010) 1.38

The relationship between homology length and crossing over during the repair of a broken chromosome. J Biol Chem (2000) 1.33

Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res (2008) 1.26

Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study. Biophys J (2007) 1.22

Photoaffinity cross-linking identifies differences in the interactions of an agonist and an antagonist with the parathyroid hormone/parathyroid hormone-related protein receptor. J Biol Chem (2000) 1.21

Structural basis for Aβ1–42 toxicity inhibition by Aβ C-terminal fragments: discrete molecular dynamics study. J Mol Biol (2011) 0.91

Structure-activity relationship of the ring portion in backbone-cyclic C-terminal hexapeptide analogs of substance P. NMR and molecular dynamics. Int J Pept Protein Res (1996) 0.79

Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J Med Chem (1996) 0.79

Identification of a contact domain between echistatin and the integrin alpha(v)beta(3) by photoaffinity cross-linking. Biochemistry (2001) 0.78